Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Piper Sandler Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)
Analysts' Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)
NewAmsterdam Pharma Company (NAMS) Receives a Buy From RBC Capital
NewAmsterdam Pharma Analyst Ratings
Strong Buy Rating for NewAmsterdam Pharma on Obicetrapib's Promising Efficacy and Market Potential
NewAmsterdam Pharma Company (NAMS) Receives a Buy From Scotiabank
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), NewAmsterdam Pharma Company (NAMS) and Humana (HUM)
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Analyst Ratings
NewAmsterdam Pharma Analyst Ratings
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk
Buy Rating Reaffirmed for NewAmsterdam Pharma With Increased Price Target Amid Promising Drug Trials and Strategic Initiatives
Buy Rating on NewAmsterdam Pharma: Underappreciated Potential of Obicetrapib in CVD Market
NewAmsterdam Pharma Analyst Ratings
NewAmsterdam Pharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nuvalent (NUVL), NewAmsterdam Pharma Company (NAMS) and Marinus (MRNS)